Spyridon Papapetropoulos
Patrimonio netto: 230 641 $ in data 31/05/2026
Patrimonio netto: 230 641 $ in data 31/05/2026
Spyridon Papapetropoulos is the founder of Encephalos Life Sciences LLC.
Dr. Papapetropoulos is President, Chief Executive Officer & Director at Bionomics Ltd. since 2023.
Dr. Papapetropoulos is Chief Executive Officer & Executive Director at Neuphoria Therapeutics, Inc. starting in 2024.
Former roles include Chief Executive Officer at SwanBio Therapeutics, Inc. from 2019 to 2020; Chairman at Lipocine, Inc. from 2022 to 2026; Independent Director at Adamas Pharmaceuticals LLC from 2020 to 2021; Chief Development Officer, SVP & Head-Development at ACADIA Pharmaceuticals, Inc. from 2019 to 2020; Chief Medical Officer & EVP-R&D at Cavion, Inc. from 2017 to 2019; and Chief Medical Officer at Vigil Neuroscience, Inc. from 2020 to 2023.
Education includes doctorates from the University of Patras and Semmelweis University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
0,32% | 16/04/2025 | 5.999.940 ( 0,32% ) | 175 258 $ | 31/05/2026 |
0,18% | 29/09/2025 | 9.888 ( 0,18% ) | 52 505 $ | 31/05/2026 |
LIPOCINE INC 0,02% | 04/06/2025 | 1.279 ( 0,02% ) | 2 878 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
Encephalos Life Sciences LLC
Encephalos Life Sciences LLC Miscellaneous Commercial ServicesCommercial Services Operates as a life sciences consulting firm | Fondatore | - |
Bionomics Ltd.
Bionomics Ltd. Pharmaceuticals: GenericHealth Technology Develops drug for treatment of central nervous system disorders | Amministratore Delegato | 05/01/2023 |
| Società | Posizione | Fine |
|---|---|---|
| LIPOCINE INC. | Presidente | 16/04/2026 |
| VIGIL NEUROSCIENCE, INC. | Direttore Tecnico/Scientifico/R&S | 04/01/2023 |
| ADAMAS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 24/11/2021 |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Amministratore Delegato | 01/10/2020 |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/09/2020 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Cavion, Inc.
Cavion, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes oncology drugs for solid tumors | Health Technology |
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets therapeutics for neurological diseases | Health Technology |
Bionomics Ltd.
Bionomics Ltd. Pharmaceuticals: GenericHealth Technology Develops drug for treatment of central nervous system disorders | Health Technology |
University of Patras
University of Patras Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Semmelweis University
Semmelweis University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lipocine, Inc.
Lipocine, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in research and development for the delivery of drugs | Health Technology |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Health Technology |
Encephalos Life Sciences LLC
Encephalos Life Sciences LLC Miscellaneous Commercial ServicesCommercial Services Operates as a life sciences consulting firm | Commercial Services |
Vigil Neuroscience, Inc.
Vigil Neuroscience, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops therapeutics for neurodegenerative diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale